Oculis Holding AG (NASDAQ:OCS – Free Report) – Research analysts at HC Wainwright increased their FY2026 EPS estimates for shares of Oculis in a research note issued on Wednesday, November 4th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($1.63) for the year, up from their previous forecast of ($1.72). HC Wainwright currently has a “Buy” rating and a $39.00 target price on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Oculis’ Q4 2026 earnings at ($0.46) EPS, Q1 2027 earnings at ($0.48) EPS, Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.49) EPS and FY2027 earnings at ($1.93) EPS.
Oculis (NASDAQ:OCS – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.10. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.26 million. Oculis had a negative net margin of 8,613.92% and a negative return on equity of 39.24%.
A number of other equities analysts have also recently issued reports on OCS. JPMorgan Chase & Co. reduced their target price on Oculis from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. Guggenheim dropped their price target on Oculis to $40.00 and set a “buy” rating on the stock in a research note on Wednesday. Wall Street Zen raised Oculis from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Thursday, October 15th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.89.
View Our Latest Research Report on OCS
Oculis Trading Down 6.2%
OCS opened at $6.83 on Friday. The company has a fifty day moving average price of $9.29 and a two-hundred day moving average price of $18.44. Oculis has a 1-year low of $6.78 and a 1-year high of $34.47. The company has a market cap of $396.00 million, a P/E ratio of -3.99 and a beta of 0.67. The company has a current ratio of 10.41, a quick ratio of 8.35 and a debt-to-equity ratio of 0.01.
Hedge Funds Weigh In On Oculis
Several large investors have recently added to or reduced their stakes in the business. Braidwell LP acquired a new position in Oculis during the 2nd quarter valued at about $11,570,000. Alps Advisors Inc. increased its holdings in Oculis by 40.7% during the 3rd quarter. Alps Advisors Inc. now owns 81,619 shares of the company’s stock worth $762,000 after purchasing an additional 23,600 shares in the last quarter. Bank of America Corp DE increased its holdings in Oculis by 9.1% during the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock worth $1,855,000 after purchasing an additional 5,813 shares in the last quarter. Squarepoint Ops LLC increased its holdings in Oculis by 326.4% during the 2nd quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock worth $854,000 after purchasing an additional 47,158 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Oculis in the first quarter worth approximately $776,000. Institutional investors own 22.30% of the company’s stock.
About Oculis
Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company’s research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.
Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision.
See Also
- Five stocks we like better than Oculis
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
